PDT Partners LLC Reduces Stake in United Therapeutics Co. (NASDAQ:UTHR)

PDT Partners LLC reduced its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 85.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 980 shares of the biotechnology company's stock after selling 5,560 shares during the quarter. PDT Partners LLC's holdings in United Therapeutics were worth $351,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of UTHR. ClariVest Asset Management LLC raised its holdings in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company's stock valued at $25,000 after buying an additional 42 shares during the period. USA Financial Formulas purchased a new stake in United Therapeutics during the 3rd quarter valued at $33,000. Brooklyn Investment Group purchased a new stake in United Therapeutics in the third quarter worth $33,000. V Square Quantitative Management LLC purchased a new stake in United Therapeutics in the second quarter worth $30,000. Finally, Innealta Capital LLC purchased a new stake in United Therapeutics in the second quarter worth $33,000. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded up $5.61 during trading on Wednesday, reaching $374.40. The stock had a trading volume of 151,191 shares, compared to its average volume of 453,867. The business has a fifty day moving average price of $368.28 and a 200-day moving average price of $337.45. The stock has a market cap of $16.72 billion, a PE ratio of 16.20, a PEG ratio of 1.08 and a beta of 0.54. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, beating the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same quarter in the prior year, the company posted $5.38 EPS. The company's quarterly revenue was up 22.9% on a year-over-year basis. Sell-side analysts expect that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Christopher Causey sold 510 shares of the company's stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $376.63, for a total transaction of $192,081.30. Following the sale, the director now owns 3,675 shares in the company, valued at $1,384,115.25. This represents a 12.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Michael Benkowitz sold 15,000 shares of the company's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $401.44, for a total value of $6,021,600.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at approximately $1,034,510.88. This trade represents a 85.34 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 119,442 shares of company stock worth $44,577,770. 11.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent analyst reports. StockNews.com upgraded United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, October 17th. The Goldman Sachs Group increased their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a "neutral" rating in a research note on Friday, November 1st. HC Wainwright raised their price target on United Therapeutics from $400.00 to $425.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Argus raised their price target on United Therapeutics from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company raised their price target on United Therapeutics from $350.00 to $380.00 and gave the company an "overweight" rating in a research note on Tuesday, August 20th. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, United Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $370.86.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.